ROTH MKM initiated coverage on GeoVax Labs with a new price target
$GOVX
Biotechnology: Pharmaceutical Preparations
Health Care
ROTH MKM initiated coverage of GeoVax Labs with a rating of Buy and set a new price target of $20.00
Get the next $GOVX alert in real time by email
Get the next $GOVX alert in real time by email
Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $GOVX
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/11/2024 | $15.00 | Buy | Alliance Global Partners |
| 7/16/2024 | $20.00 | Buy | ROTH MKM |
Presenting on the Emerging Growth Conference 80 Day 2 on March 27 Register Now
MIAMI, March 26, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 80th Emerging Growth Conference on March 26 & 27, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1 - TodayMarch 26, 2025 11:00Virtual Lobby opens.Register for the Conference. If you already registered, go back to
Presenting on the Emerging Growth Conference 80, Day 1 on March 26 - Register Now
MIAMI, March 25, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com, a leading independent small cap media portal, announces the schedule of the 80th Emerging Growth Conference on March 26 & 27, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com. For updates, follow us on Twitter. Day 1March 26, 2025 11:00Virtual Lobby opens.Register for the Conference. If you already registered, go
Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now
MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Conference on February 18 & 19, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 2 - TodayFebruary 19, 2025 Replay Day 1 here:https://emerginggrowt
Alliance Global Partners initiated coverage on GeoVax Labs with a new price target
Alliance Global Partners initiated coverage of GeoVax Labs with a rating of Buy and set a new price target of $15.00
ROTH MKM initiated coverage on GeoVax Labs with a new price target
ROTH MKM initiated coverage of GeoVax Labs with a rating of Buy and set a new price target of $20.00
President, CEO Dodd David A bought $10,800 worth of shares (10,000 units at $1.08), increasing direct ownership by 38% to 36,661 units (SEC Form 4)
4 - GeoVax Labs, Inc. (0000832489) (Issuer)
CFO Reynolds Mark bought $7,343 worth of shares (6,800 units at $1.08), increasing direct ownership by 94% to 14,013 units (SEC Form 4)
4 - GeoVax Labs, Inc. (0000832489) (Issuer)
President, CEO Dodd David A bought $15,600 worth of shares (8,000 units at $1.95), increasing direct ownership by 43% to 26,661 units (SEC Form 4)
4 - GeoVax Labs, Inc. (0000832489) (Issuer)
President, CEO Dodd David A bought $10,800 worth of shares (10,000 units at $1.08), increasing direct ownership by 38% to 36,661 units (SEC Form 4)
4 - GeoVax Labs, Inc. (0000832489) (Issuer)
CFO Reynolds Mark bought $7,343 worth of shares (6,800 units at $1.08), increasing direct ownership by 94% to 14,013 units (SEC Form 4)
4 - GeoVax Labs, Inc. (0000832489) (Issuer)
SEC Form 4 filed by President, CEO Dodd David A
4 - GeoVax Labs, Inc. (0000832489) (Issuer)
SEC Form EFFECT filed by GeoVax Labs Inc.
EFFECT - GeoVax Labs, Inc. (0000832489) (Filer)
SEC Form EFFECT filed by GeoVax Labs Inc.
EFFECT - GeoVax Labs, Inc. (0000832489) (Filer)
SEC Form EFFECT filed by GeoVax Labs Inc.
EFFECT - GeoVax Labs, Inc. (0000832489) (Filer)
GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board
Strategic Appointment Enhances GeoVax's Leadership and Expertise in Vaccine Development ATLANTA, GA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the appointment of Teresa Lambe, PhD, OBE, FMedSci to its Scientific Advisory Board. Professor Lambe is the Calleva Head of Vaccine Immunology at the Oxford Vaccine Group within the University of Oxford and a Principal Investigator at the Pandemic Sciences Institute (PSI). She served as one of the Principal Investigators who oversaw the Oxford/AstraZeneca vaccine program; she co-designed the vacci
GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology
Strengthening GeoVax's Team Advancing Gedeptin® Clinical Program ATLANTA, GA, Jan. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the appointment of J. Marc Pipas, M.D., to serve as the Company's Executive Medical Director, Oncology. Kelly McKee, M.D., MPH, GeoVax Chief Medical Officer, commented, "Dr. Pipas' addition to our team represents an important step forward in the strengthening of GeoVax's organizational and operational resources to support advancement of our principal oncology asset, Gedeptin®, through clinical development
Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax
First Woman President and CEO of MSM and Internationally Recognized Health Equity Advocate Joins in GeoVax Special Advisory Role ATLANTA, GA, Dec. 20, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today the appointment of Valerie Montgomery Rice, MD, FACOG, Morehouse School of Medicine President and CEO, as Special Advisor to the Chairman/CEO and Board of Directors of GeoVax. Dr. Montgomery Rice brings GeoVax exceptional expertise and highly recognized experience at the highest levels of healthcare leadership, patient care, biomedical resear
GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update
Progress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVID-19 vaccine Phase 2 trials expected during fourth quarter 2024 Gedeptin® on track to advance into Phase 2 clinical trial for first recurrent head and neck cancer in the first half of 2025 GEO-MVA Mpox vaccine advancing with cGMP clinical batch anticipated during fourth quarter 2024 Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced financial results for the third quarter end
GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024
GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024, after the close of U.S. markets. Following the release, management will host a live conference call and webcast, including Q&A, at 4:30 p.m. ET to provide a corporate update and discuss financial results. Conference Call Details To access the live conference call, participants may register here. The live audio webcast of the call will be available
GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update
Awarded BARDA Project NextGen (PNG) contract to advance GeoVax's multi-antigen vaccine candidate, GEO-CM04S1, into 10,000-participant randomized, comparative Phase 2b COVID-19 vaccine study BARDA PNG award represents greater than $350 million in support of PNG GEO-CM04S1 clinical trial, including direct funding of CRO partner Allucent Multiple planned data readouts for GEO-CM04S1 throughout second half of 2024;Gedeptin® to advance into expanded Phase 2 clinical trial with activation in the first half of 2025 Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, GA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developin
Amendment: SEC Form SC 13G/A filed by GeoVax Labs Inc.
SC 13G/A - GeoVax Labs, Inc. (0000832489) (Subject)
SEC Form SC 13G filed by GeoVax Labs Inc.
SC 13G - GeoVax Labs, Inc. (0000832489) (Subject)
SEC Form SC 13G/A filed
SC 13G/A - GeoVax Labs, Inc. (0000832489) (Subject)